Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
City Therapeutics prices IPO at $18/share, raising $200M for RNAi therapeutics development.
Amount Raised
$200 Million
Round Type
IPO
Investors
Description
City Therapeutics priced its initial public offering at $18.00 per share, raising approximately $200 million in gross proceeds from 11.1 million shares. The clinical-stage biotechnology company, which develops next-generation RNA interference therapeutics, began trading on NASDAQ under ticker CTY on October 16, 2026. Goldman Sachs, Jefferies, Stifel, and Oppenheimer served as joint book-running managers. The offering includes a 30-day underwriter option to purchase an additional 1.67 million shares at the same price.
Fundz sees it the moment City Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
City Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.